Bad news!   http://www.fiercebiotech.com/story/ptcs-lead-drug-ataluren-flunks-phiib/2010-03-03   SOUTH PLAINFIELD, NJ and CAMBRIDGE, MA – March 03, 2010 – PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (…